Generic placeholder image

Current Vascular Pharmacology

Eiditor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Omentin: Linking Metabolic Syndrome and Cardiovascular Disease

Author(s): Ji-Yin Zhou, Lawrence Chan and Shi-Wen Zhou

Volume 12 , Issue 1 , 2014

Page: [136 - 143] Pages: 8

DOI: 10.2174/1570161112999140217095038

Price: $58

Abstract

Omentin is an adipokine preferentially produced by visceral adipose tissue with insulin-sensitizing effects. Its expression is reduced in obesity, insulin resistance and type 2 diabetes. Omentin is also positively related with adiponectin, high-density lipoprotein levels and negatively related with body mass index, waist circumference, insulin resistance, triglyceride and leptin levels. Lower plasma omentin levels contribute to the pathogenesis of insulin resistance, type 2 diabetes and cardiovascular diseases in obese or overweight patients. Omentin has anti-inflammatory, antiatherogenic, anti-cardiovascular disease and antidiabetic properties. With respect to vascular biology, omentin causes vasodilatation of blood vessels and attenuates C-reactive protein-induced angiogenesis. The ability of omentin to reduce insulin resistance in conjunction with its anti-inflammatory and anti-atherogenic properties makes it a promising therapeutic target. Thus, omentin may have beneficial effects on the metabolic syndrome and could potentially be used as a biologic marker and/or pharmacologic agent/target in this respect.

Keywords: Cardiovascular diseases, diabetes, inflammation, metabolic syndrome, omentin.


Related Journals
Related eBooks
Article Metrics
56
Related Articles
© 2020 Bentham Science Publishers